Therapeutic Potential of Non-Coding RNAs and TLR Signalling Pathways in Rheumatoid Arthritis

Background: Rheumatoid Arthritis (RA) is a common connective tissue disease, characteristic of chronic and invasive synovitis in single or multiple joints and vasculitis. RA is a heterogeneous disease with unclear pathogenesis. Therefore, exploring the etiology and pathogenesis of the disease is essential for identifying new promising treatment strategies for RA. Accumulated data have implicated the significant role of non-coding RNA in RA, some of which are demonstrated to regulate inflammation and autoimmunity in RA through the Toll-Like Receptor (TLR) signaling pathway. To clarify the mechanism of non-coding RNA regulating the generation of proinflammatory mediators is helpful for understanding the pathogenesis of RA. Moreover, these well established non-coding RNAs can serve as novel biotargets for RA diagnosis and treatment. Conclusion: Here, we summarize currently available data on non-coding RNAs, TLRs, and the underlying molecular mechanisms in RA. This review will provide insight into the potential use of noncoding RNA as disease diagnosis and treatment markers for RA.

Automated summary

Non-coding RNAs play a significant role in rheumatoid arthritis by regulating inflammation and autoimmunity, serving as potential new treatment strategies. Understanding the mechanism of non-coding RNA regulation can provide insight into the pathogenesis of the disease and offer new approaches for diagnosis and treatment.